The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial |
Effectiveness of COVID-19 Vaccines to Prevent Long COVID: Data from Norway |
Fibrin Drives Thromboinflammation and Neuropathology in COVID-19 |
Post-Acute Sequelae of COVID (PASC or Long COVID): An Evidenced-based Approach
Effectiveness of Historical Smallpox Vaccination against Mpox Clade II in Men in Denmark, France, the Netherlands and Spain, 2022 |
Pemivibart is Less Active against Recent SARS-CoV-2 JN.1 Sublineages | U.S. Real-World Effectiveness Study of Nirmatrelvir/Ritonavir in Preventing Hospitalization of High-Risk COVID-19 Patients |
COVID-19 and Mental Illnesses in Vaccinated and Unvaccinated People | Post-acute COVID-19 Outcomes Including Participant-reported Long COVID: Amubarvimab/romlusevimab versus Placebo in the ACTIV-2 Trial
What Is the Economic Benefit of Annual COVID-19 Vaccination From the Adult | Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023–January 2024 | Uptake of COVID-19 vaccines and association with hospitalisation due to COVID-19 in pregnancy: Retrospective cohort study | The Novavax Heterologous Coronavirus Disease 2019 Booster Demonstrates Lower Reactogenicity Than Messenger | Characterizing Long COVID in Children and Adolescents
Onward Virus Transmission after Measles Secondary Vaccination Failure | Single Monoclonal Antibodies Should Not be Used for COVID-19 Therapy: A Call for Antiviral Stewardship |
Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort | Risk Factors for Long COVID Syndrome in Postmenopausal Women with Previously Reported Diagnosis of COVID-19 |
Long-COVID Symptom Monitoring: Insights from a Two-year Telemedicine Study
Personal Protective Effect of Wearing Surgical Face Masks in Public Spaces on Self-reported Respiratory Symptoms in Adults |
Cohort Study of Cardiovascular Safety of Different COVID-19 Vaccination Doses among 46 million Adults in England | Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2 among adults aged ≥ 65 years | Incidence of Diabetes after SARS-CoV-2 Infection in England |
Post-COVID-19 Respiratory Sequelae Two Years after Hospitalization |
Incidence of Hearing Loss Following COVID-19 among Young Adults in South Korea | The Effect of Long-term COVID-19 Infection on Maternal and Fetal Complications
Insights from an N3C RECOVER EHR-based Cohort Study Characterizing SARS-CoV-2 Reinfections and Long COVID |
Cost-effectiveness of COVID Rapid Diagnostic Tests for Patients with Severe/Critical Illness in Low- and Middle-income Countries: A Modeling Study |
Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 Vaccine |
Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization in Adults With COVID-19 | Tracking cognitive trajectories in older survivors of COVID-19 up to 2.5 years post-infection
Post–Acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 | Oral Nirmatrelvir–Ritonavir as Postexposure Prophylaxis for COVID-19 |
Combined Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Reduces Molnupiravir-Induced Mutagenicity |
Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19 |
Comparative Effectiveness of Combination Therapy with Nirmatrelvir–ritonavir and Remdesivir versus Monotherapy with Remdesivir | Postacute Sequelae of SARS-CoV-2 Infection |
The Efficacy of Antivirals, Corticosteroids, and mAbs as Acute COVID Treatments
Proton Pump Inhibitors and Risk of COVID-19 Infection in Children |
Long Covid The Answers
Effectiveness and Safety of Molnupiravir in the Intended-Use Population: An Observational Cohort Study | The Life-saving Benefit of Dexamethasone in Severe COVID-19 is Linked to a Reversal of Monocyte Dysregulation | EEG Signatures of Cognitive Decline after Mild SARS-CoV-2 Infection: An Age-dependent Study | Tissue-based T Cell Activation and Viral RNA Persist for Up to 2 Years after SARS-CoV-2 Infection
A comprehensive educational resource on all aspects of parasitic diseases and their impact on humanity around the globe.
Help bring the latest medical and basic biological information pertaining to diseases caused by eukaryotic parasites to every practicing physician and medical student within the United States.
English 
Spanish 